首頁 > 市場調查報告書 > 製藥

孤兒藥

法布瑞氏症市場規模、佔有率和成長分析：按療法、給藥途徑、最終用戶、分銷管道、發病時間和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2091787

法布瑞氏症市場規模、佔有率和成長分析：按療法、給藥途徑、最終用戶、分銷管道、發病時間和地區分類－2026-2033年產業預測

Fabry Disease Market Size, Share, and Growth Analysis, By Treatment Type, By Route of Administration, By End User, By Distribution Channel, By Disease Onset, By Region - Industry Forecast 2026-2033

出版日期: 2026年07月15日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球法布瑞氏症市場價值為 17.6 億美元，預計到 2033 年將從 2025 年的 19.2 億美元成長至 38 億美元，預測期（2026-2033 年）的複合年成長率為 8.9%。

法布瑞氏症是一種X連鎖溶小體儲積症，其特徵是α-半乳糖苷酶A缺乏，導致Globotriaosylceramide在體內重要系統中有害積聚。診斷工具和酵素替代療法（ERT）的引入塑造了全球治療市場，並顯著改善了患者的預後。酵素的仿單標示外使用為治療研發帶來了挑戰，但阿加拉糖酶α的核准進一步推動了這一進程。為了克服ERT的局限性，例如需要終身靜脈注射，隨著口服療法和精準醫療（包括基因編輯技術）的引入，市場呈現成長跡象。口服藥物米格司他顯示出更高的療效和遵守用藥性，從而降低了醫療成本，並促使保險公司考慮類似的治療方案。早期基因療法也顯示出令人鼓舞的結果。

全球法布瑞氏症市場成長要素

全球法布瑞氏症市場的主要促進因素是醫療專業人員和患者對該疾病的認知度和盛行率不斷提高。醫學研究的進步使人們對法布瑞氏症（一種罕見的遺傳性溶小體儲積症）有了更深入的了解，並實現了更精準的診斷。除了認知度的提高，新療法和酵素替代療法的研發也改善了患者的生活品質。此外，對罕見疾病研究投入的增加以及患者權益倡導組織的建立進一步提高了人們對法布瑞氏症的關注度，最終推動了市場對有效療法的需求。

全球法布瑞氏症市場面臨的限制因素

全球法布瑞氏症市場的主要限制因素之一是酵素替代療法（ERT）和其他治療的高昂費用。這些治療往往會對患者和醫療系統造成沉重的經濟負擔，使得患者難以獲得治療，尤其是在發展中地區。此外，醫護人員和病患對法布瑞氏症的認知不足會導致漏診和治療延誤，進一步阻礙市場成長。此外，嚴格的監管條件和新療法臨床試驗的複雜性也進一步阻礙了這種罕見遺傳疾病治療方案的擴展。

全球法布瑞氏症市場趨勢

受基因療法進展的推動，全球法布瑞氏症市場目前正經歷著強勁的發展勢頭。 CRISPR和鹼基編輯等創新基因編輯技術正從實驗階段走向監管核可階段，從而實現精準的基因修飾，直擊法布里病的根本病因。這一轉變正為一次性根治性治療鋪平道路，擺脫了通常需要終身服藥的傳統酵素替代療法。因此，市場投資、合作和積極的臨床開發活動激增，從根本上改變了相關人員的預期，並提高了患者照護取得突破性成果的可能性。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Amicus Therapeutics, Inc.
ISU Abxis Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
Protalix BioTherapeutics, Inc.
Idorsia Pharmaceuticals Ltd.
Sangamo Therapeutics, Inc.
Freeline Therapeutics Holdings plc
Chiesi Farmaceutici SpA
Yuhan Corporation
Green Cross Pharma Pte Ltd.
uniQure NV
Abeona Therapeutics, Inc.
Codexis, Inc.
Centogene NV
Selecta Biosciences, Inc.

結論與建議

簡介目錄

Product Code: SQMIG35I3149

Global Fabry Disease Market size was valued at USD 1.76 Billion in 2024 and is poised to grow from USD 1.92 Billion in 2025 to USD 3.8 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).

Fabry disease is a rare X-linked lysosomal storage disorder characterized by the deficiency of a-galactosidase A, leading to harmful accumulation of globotriaosylceramide in critical bodily systems. The global treatment market has emerged with the introduction of diagnostic tools and enzyme replacement therapy (ERT), significantly enhancing patient outcomes. Although treatment development faced challenges due to off-label enzyme use, the approval of agalsidase alfa has sparked advancements. The market is poised for growth with the introduction of precision medicine, including oral therapies and gene-editing technologies, addressing limitations of ERT such as lifelong intravenous administration. Oral migalastat has shown improved efficacy and adherence, reducing healthcare costs and prompting insurance providers to consider similar treatment options, while early-phase gene therapy demonstrates promising results.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fabry Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fabry Disease Market Segments Analysis

Global fabry disease market is segmented by treatment type, route of administration, end user, distribution channel, disease onset and region. Based on treatment type, the market is segmented into Enzyme Replacement Therapy (ERT), Oral Chaperone Therapy, Substrate Reduction Therapy (SRT), Gene Therapy and Symptomatic / Supportive Care. Based on route of administration, the market is segmented into Intravenous and Oral. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Homecare Settings. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on disease onset, the market is segmented into Classic (Early-Onset) Fabry Disease and Late-Onset Fabry Disease. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fabry Disease Market

A key market driver for the global Fabry disease market is the increasing prevalence and awareness of the disease among healthcare professionals and patients. As medical research advances, the understanding of Fabry disease, a rare genetic lysosomal storage disorder, is improving, leading to more accurate diagnoses. This heightened awareness is coupled with the development of novel therapies and enzyme replacement treatments, which are enhancing the quality of life for affected individuals. Additionally, growing investment in rare disease research and the establishment of patient advocacy groups are further amplifying focus on Fabry disease, ultimately driving demand for effective therapeutic options in the market.

Restraints in the Global Fabry Disease Market

One of the key market restraints for the global Fabry disease market is the high cost associated with enzyme replacement therapies (ERTs) and other treatment options. These therapies often place a significant financial burden on patients and healthcare systems, leading to accessibility challenges, particularly in developing regions. Furthermore, the limited awareness of Fabry disease among healthcare professionals and patients may result in underdiagnosis and delayed treatment initiation, further hampering market growth. Additionally, the stringent regulatory landscape and the complexities associated with clinical trials for new therapies pose further obstacles in advancing treatment options for this rare genetic disorder.

Market Trends of the Global Fabry Disease Market

The Global Fabry Disease market is currently witnessing significant momentum driven by advancements in gene therapy. Innovative gene editing technologies, notably CRISPR and base editing, are transitioning from experimental stages to regulatory approval, enabling precise gene corrections that address the underlying causes of Fabry disease. This shift is paving the way for one-time curative treatments, moving away from traditional enzyme replacement therapies, which typically require lifelong administration. As a result, the market is experiencing a surge in investment, collaborative partnerships, and active clinical development, fundamentally reshaping stakeholder expectations and enhancing the potential for transformative outcomes in patient care.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Fabry Disease Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Enzyme Replacement Therapy (ERT)
Oral Chaperone Therapy
Substrate Reduction Therapy (SRT)
Gene Therapy
Symptomatic / Supportive Care

Global Fabry Disease Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous
Oral

Global Fabry Disease Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Homecare Settings

Global Fabry Disease Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Fabry Disease Market Size by Disease Onset & CAGR (2026-2033)

Market Overview
Classic (Early-Onset) Fabry Disease
Late-Onset Fabry Disease

Global Fabry Disease Market Size & CAGR (2026-2033)

North America (Treatment Type, Route of Administration, End User, Distribution Channel, Disease Onset)
- US
- Canada
Europe (Treatment Type, Route of Administration, End User, Distribution Channel, Disease Onset)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Route of Administration, End User, Distribution Channel, Disease Onset)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Route of Administration, End User, Distribution Channel, Disease Onset)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Route of Administration, End User, Distribution Channel, Disease Onset)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Amicus Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ISU Abxis Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JCR Pharmaceuticals Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Protalix BioTherapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Idorsia Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Freeline Therapeutics Holdings plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi Farmaceutici S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yuhan Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Pharma Pte Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
uniQure N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abeona Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Codexis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Centogene N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Selecta Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments